Inventor
WITTEKIND MICHAEL
US27 patents
⚠️ This page may combine multiple inventors who share the name “WITTEKIND MICHAEL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CONTRAFECT CORP
12 patentsUS10744189B2Aug 18, 2020
Lysin polypeptides active against Gram-negative bacteria
CONTRAFECT CORP8 citations82
US9499594B2Nov 22, 2016
Biofilm prevention, disruption and treatment with bacteriophage lysin
CONTRAFECT CORP6 citations82
US11413334B2Aug 16, 2022
Lysin polypeptides active against Gram-negative bacteria
CONTRAFECT CORP2 citations71
US9889181B2Feb 13, 2018
Bacteriophage lysin and antibiotic combinations against gram positive bacteria
CONTRAFECT CORP2 citations70
US9718875B2Aug 1, 2017
Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
CONTRAFECT CORP2 citations69
US11357833B2Jun 14, 2022
Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
CONTRAFECT CORP0 citations62
US12491245B2Dec 9, 2025
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
CONTRAFECT CORP0 citations60
US11524046B2Dec 13, 2022
Biofilm prevention, disruption and treatment with bacteriophage lysin
CONTRAFECT CORP0 citations60
US11246928B2Feb 15, 2022
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
CONTRAFECT CORP0 citations60
US11827693B2Nov 28, 2023
Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy
CONTRAFECT CORP0 citations59
US10813983B2Oct 27, 2020
Bacteriophage lysin and antibiotic combinations against gram positive bacteria
CONTRAFECT CORP0 citations49
US10639370B2May 5, 2020
Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
CONTRAFECT CORP0 citations49
BRISTOL MYERS SQUIBB CO
7 patentsUS7858739B2Dec 28, 2010
Inhibitors of type 2 vascular endothelial growth factor receptors
BRISTOL MYERS SQUIBB CO84 citations98
US7847062B2Dec 7, 2010
Pharmacokinetic modulation and compositions for modified FN3 polypeptides
BRISTOL MYERS SQUIBB CO77 citations98
US9328157B2May 3, 2016
Inhibitors of type 2 vascular endothelial growth factor receptors
BRISTOL MYERS SQUIBB CO26 citations97
US9862758B2Jan 9, 2018
Inhibitors of type 2 vascular endothelial growth factor receptors
BRISTOL MYERS SQUIBB CO20 citations94
US6333186B1Dec 25, 2001
Modified forms of Hepatitis C NS3 protease for facilitating inhibitor screening and structural studies of protease: inhibitor complexes
BRISTOL MYERS SQUIBB CO20 citations88
US10995131B2May 4, 2021
Libraries of modified fibronectin type III tenth domain-containing polypeptides
BRISTOL MYERS SQUIBB CO1 citations73
US6800456B2Oct 5, 2004
Modified forms of hepatitis C NS3 protease for facilitating inhibitor screening and structural studies of protease:inhibitor complexes
BRISTOL MYERS SQUIBB CO11 citations69